ROCKVILLE, Md., Feb. 8, 2006 (PRIMEZONE) -- Cytomedix, Inc. (AMEX:GTF), a biotechnology company specializing in the research, development, licensing, and systems for treating non-healing chronic wounds including diabetic ulcers, today announced that Chairman and Chief Executive Officer Kshitij Mohan was interviewed by The Wall Street Reporter and discussed the Company's submission of a pre-market 510(k) application to the U.S. Food and Drug Administration (FDA) seeking clearance for its AutoloGel(tm) System.
